The present invention may be included in the field of biotechnology. The invention refers to regulatory polynucleotide sequences (such as promoters) derived from hexamerin family genes in insects, and their use for foreign protein expression in insect cells and insect larva, for example using the baculovirus expression vector.
The baculovirus-insect cell expression system is versatile and widely used for producing heterologous (both native and recombinant) proteins. This system is universally recognized as one of the most powerful and versatile to produce recombinant protein of any size. It is based on two main characteristics: the high levels of protein expression achieved and the correct folding of the proteins to become bioactive, while occurring major posttranslational modifications of mammalian cells. In addition, development times of this system are shorter and the genetic stability of the recombinant virus is very high. The baculovirus genome contains two strong promoters called polyhedrin promoter (pL), that is the strongest promoter known among higher organisms, and the promoter p10 (p10 protein). The pL promoter can be used to control the expression of virtually any gene. It is far more rapid and less costly to engineer a baculovirus for protein production than any other advanced production systems based on transformed animal cells or transgenic animals. Nevertheless, previous commercially available promoters have some disadvantages, such as the very late stage in which they promote gene expression. At that time the cellular machinery is largely affected, and then yields of heterologous proteins expressed in insect cells may be impaired, due to incomplete processing and aggregation. These limitations may be due to the deterioration of host cell factors as the viral infection progresses. In order to solve that problem the present invention suggests the use of earlier promoters with stable expression, which are at least as strong as the polyhedrin promoter, as a very interesting option to offset the effects of host cell degradation and, at the same time, to achieve high expression levels of heterologous proteins. The present invention wants to recalls attention to the fact that the transition of the larva (immature) to the adult (mature) form is accomplished by the activation and suppression of a number of genes in various tissues (insect metamorphic development). Among metamorphosis-associated proteins there is a family known as hexamerins that are expressed at very high level during the last instar. These proteins are mostly hemolymph storage proteins which are used during post-larval development. The highest level of the hexamerins can be observed during the first 48 hours of the fifth instar about a four times more after that period (
Thus, the present invention provides regulatory polynucleotide sequences, such as pB1 (SEQ ID NO 1) and/or pB2 (SEQ ID NO 2), coming from the sequences that regulate the hexamerin family gene expression. These proteins show the highest expression during the fifth instar, at a very high percentage after the first 48 hours of this larva development period, presenting a very rapid accumulation in a short period of time (
The sequences of the promoters of the invention come from the sequences that regulate the hexamerin family genes (BJHSP1 and BJHSP2) expression, but having some mutations not comprised in the original regulatory nucleotide sequences of said hexamerin family genes. Said hexamerins were isolated form Trichoplusia ni (T. ni) larvae and identified in a band of 80 KDa by mass spectrometry analysis (
The main advantage of the promoters of the invention, specifically pB2, is that they produce an earlier and stronger expression of the protein of interest when compared with the known very late promoters used nowadays in baculovirus expression systems.
In a preferred embodiment, the present invention also includes the combination of the promoters of the invention pB1 and pB2 (preferably pB2) with any other promoter, for example pL or p10 (preferably pL). Surprisingly, when such a combination was carried out a synergetic effect was achieved. When a baculovirus expression vector comprising a pLpB2 promoter was tested, the expression levels of the proteins of interest were increased up to 61%-375% (depending on the time of infection) with respect to the use of pL promoter alone. This embodiment is very important for the purpose of the present invention because the promoter pL is, nowadays, generally used in the biotechnology industry.
In other preferred embodiment, the present invention also refers to the combination of the promoter of the invention (pB1 and pB2) thereof: pB1-pB1, pB2-pB2 and pB1-pB2.
No activity of the promoters of the invention was detected in mammalian cells. Then, the present invention also provides two safety promoters for development of recombinant baculoviruses.
Therefore, the present invention elucidates (see the detailed description of the invention) that regulatory polynucleotide sequences (promoters), more effective than those comprised in the state of the Art, could be derived from any polynucleotide sequence located upstream of the open reading frames of the genes that encode for hexamerin family proteins. Therefore, any regulatory polynucleotide sequence derived from any polynucleotide sequence located upstream of the open reading frames of the genes that encode for hexamerin family proteins may be included in the aim of the present invention.
For the only purpose of present invention the following terms are defined:
The present invention provides regulatory polynucleotide sequences, such as the promoters pB1 and pB2 characterized, respectively, by the SEQ ID NO: 1 and the SEQ ID NO: 2, and derived from polynucleotide sequences located upstream of the open reading frames of the genes that encode for hexamerin family proteins in insect larvae. The present invention further refers to the use of such a regulatory polynucleotide sequences for constructing insect expression vectors such as Baculovirus and for expressing heterologous proteins in cells, preferably insect cells. Sequences of the promoters pB1 and pB2 come from the T. ni hexamerins BJHSP1 and BJHSP2 respectively, which are expressed at high level during the fifth instar and with very high transcriptional activity during the first 48 h of this period (
The pB1 sequence is comprised by 1057 nucleotides (SEQ ID NO 1) and derived from the 5′ region upstream the initiation codon of the gene encoding the BJHSP1 protein which is the Basic protein 1 suppressible by juvenile hormone. The sequence was amplified from the T. ni genomic DNA by using two specific primers: SEQ ID NO: 3 and SEQ ID NO: 4. The fragment was then cloned in the pGEM-Teasy commercial vector (Promega).
The pB2 sequence is comprised by 1041 nucleotides (SEQ ID NO 2) and derived from the 5′ region upstream the initiation codon of the gene encoding the BJHSP2 protein which is the Basic protein 2 suppressible by juvenile hormone. The sequence was amplified from the T. ni genomic DNA by using two specific primers: SEQ ID NO: 5 and SEQ ID NO: 6. The fragment was then cloned in the pGEM-Teasy commercial vector (Promega).
The pB1 and pB2 sequences were extracted from pGEM-Teasy with BamHI and SphI enzymes and cloned into those sites in the pFasTBac dual commercial plasmid (INVITROGEN). This pFasTBac dual vector opened with the mentioned enzymes has the baculovirus promoter sequences eliminated (the vectors obtained were named as: pFBpB1 and pFBpB2). All of them present a cloning site to introduce the cDNA of interest. These were used to generate the recombinant baculoviruses that are able to infect and replicate in insect cells and insect larvae. Additionally, pB2 sequence was extracted by digestion with the restriction enzymes NotI and PstI (both restriction sites coming from the pGemT easy vector) and cloned into the same sites in the pFasTBac 1 commercial vector (INVITROGEN), after the pL promoter sequence. The vector obtained was named as: pFBpLpB2.
Therefore, the first embodiment of the present invention refers to a method for developing expression regulatory polynucleotide sequences: SEQ ID NO: 1 (pB1) and SEQ ID NO: 2 (pB2). Said method comprises the isolation of any polynucleotide sequence located upstream of the open reading frames of the genes that encode for the hexamerin family proteins. Once the regulatory polynucleotide sequences were sequenced, they were amplified by conventional means.
In a preferred embodiment of the invention the upstream polynucleotide sequence of hexamerin open reading frames belongs to an insect, preferably Trichoplusia ni.
The second embodiment of the present invention refers to regulatory polynucleotide sequences: SEQ ID NO: 1 (pB1), SEQ ID NO: 2 (pB2), or any partial fragment thereof, characterized by comprising any sequence derived from any regulatory nucleotide region located upstream of the open reading frames of the genes that encode for the hexamerin family proteins. These promoter sequences present regulatory DNA motifs involved in the modulation of transcriptional activity. Therefore, these sequences can be regulated by hormones during larva development but other signals and also potentially in cell cultures in the context of expression vectors.
In a preferred embodiment the regulatory polynucleotide sequences of the invention: SEQ ID NO: 1 (pB1) and SEQ ID NO: 2 (pB2) are combined with any other regulatory polynucleotide sequence, preferably the promoter pL (promoter of the protein polyedrin) or p10 (promoter of the protein p10) giving rise to different combinations: pLpB2, pLpB1, p10pB2 and p10pB1. The invention provides a very strong promoter sequence when the pL sequence (polyedrin promoter) is combined with the pB2 sequence.
In other preferred embodiment the regulatory polynucleotide sequences of the invention: SEQ ID NO: 1 (pB1) and SEQ ID NO: 2 (pB2) are combined thereof giving rise to different combinations: pB1pB2, pB1pB1 (at least twice repeated) and pB2pB2 (at least twice repeated). It has been shown that the tandemly located promoters increase efficiency of recombinant protein expression in bacteria and plants (Il'ichev A A et al., Genetika. 1987 23:197-201; Kay R et al., Science. 1987 Jun. 5; 236(4806):1299-1302).
The third embodiment of the present invention refers to the use of any of the above mentioned regulatory polynucleotide sequences for constructing expression vectors, preferably a baculovirus or a plasmid.
The fourth embodiment of the invention refers to expression vectors characterized by comprising any of the above explained regulatory polynucleotide sequences and at least a sequence encoding for a protein of interest. In a preferred embodiment the vector is a baculovirus or a plasmid.
The fifth embodiment of the present invention refers to cells transformed, transfected by the expression vector or infected with a recombinant virus used as a vector as described in the previous paragraph. In a preferred embodiment the cells are insect cells preferably sf9 or sf21 from Spodoptera frugiperda.
The sixth embodiment of the present invention refers to insect larvae transformed, transfected or infected with the above mentioned expression vectors.
The seventh embodiment of the present invention refers to a method for producing recombinant proteins in insect cells or insect larvae with the above mentioned expression vectors and the extraction and purification of the recombinant protein of interest by conventional means.
The eight embodiment of the present invention refers to the use of said expression vector for producing recombinant proteins.
The ninth embodiment of the present invention refers to the use of said cells for producing recombinant proteins.
The last embodiment of the preset invention refers to the use of said insect larvae as a biofactory for producing recombinant proteins.
Plasmids were deposited in the Spanish Type Culture Collection (CECT); University of Valencia, Spain with the accession number CECT 7431, on the date Jul. 2, 2008.
This invention is best illustrated by the following examples, which should not be interpreted to be a limitation imposed on the scope thereof. On the contrary, it must be clearly understood that other embodiments, modifications and equivalents thereof may be used which this description may suggest to those skilled in the Art without moving away from the spirit of this invention and/or the scope of the attached claims.
The examples of the present invention show that the protein expression takes place at an earlier post-infection time as compared when conventional promoters were used. Moreover, in case of the pB2 and pLpB2 promoter sequences, the expression levels were higher as compared with those achieved in the state of the Art (promoter pL) at both early and late post-infection times.
The GFP extracted from the pFBpLGFP plasmid by the SphI restriction enzyme was cloned into the SphI restriction site of the pFBpB1 or pFBpB2 plasmids. The donor-expression plasmids obtained were denominated pFBpB1GFP and pFBpB2GFP respectively. In all the cases the pL sequence was eliminated, so the GFP expression was only due to the activity of the different insect promoters by themselves (
In the other hand, the pB2 promoter flanked by the NotI and PstI restriction sites were ligated into the pFBpLGFP also opened by the same restriction enzymes. The donor-expression plasmids obtained were denominated pFBpLpB2GFP and contained the GFP encoding gene under the control of the double promoter pL and pB2 (
The resulting plasmids were characterized by automated sequencing and used to generate the recombinant baculovirus BacpB2GFP, BacpB1GFP and BacpLpB2GFP using the Bac-to-Bac® Baculovirus expression system (Invitrogen, USA) following the manufacture's instructions. Briefly, the resulting donor-expression plasmids were used to transfer DH10Bac™ E. coli cells for the transposition into the recombinant bacmid. One μg of each bacmid was used to transfect 1×106 Spodoptera frugiperda sf21 cells using Cellfectin® Reagent. The P1 viral stock was obtained after 72 h of incubation at 27° C. The baculovirus was amplified following the manufacturer's instructions. The sf21 insect cells were grown on BD BaculoGold™ TNM-FH Insect Medium (BD Biosciences) supplemented with 50 mg/mL gentamycin. The baculovirus BacpLGFP, previously generated in our laboratory, was obtained following identical protocol by using pFBpLGFP plasmid.
Cells were then infected at a multiplicity of infection of 0.1 pfu and cells were pelleted at 16 h, 24 h, 48 h or 72 h post-infection by centrifugation at 2000 rpm for 5 min.
The infected cells were also photographed at different times post-infection in a fluorescence microscope and the pictures are shown in
Fifth-instar Trichoplusia ni larvae were injected with the recombinant baculoviruses near the proleg (forward the body cavity) using 104-105 pfu/larva dose. Infected larvae were kept in growth chambers at 28° C. and collected at 72 h. Lower panel of
Pelleted cells from a P6 well plate (2×106 cells/well were infected at 0.1 pfu/well) were resuspended in 30 μl of 150 mM NaCl, 1% NP-40, 0.1% SDS, 50 mM Tris pH 8, protease inhibitors (Complete®, Roche), 2-mercaptoethanol (RIPA buffer), keeped on ice for 30 min and clarified by centrifugation at 2000 g for 5 min at 4° C. to remove cellular debris.
40 μg of total soluble proteins (TSP) were separated on 12% SDS (w/v) polyacrylamide gels. Proteins were stained with Coomassie Brilliant Blue G-250 (BioRad) or transferred onto nitrocellulose membranes (Hybond C, GE Healthcare), blocked overnight in PBS with 0.1% (v/v) Tween 20 (PBS-T) and 4% skimmed milk (PBS-TM), and incubated for 1 h with GFP primary antibody (Chemicon) diluted 1:1000 and Actine primary antibody (Sigma) diluted 1:500 in PBS-TM. After 2 washes of 10 min in PBS-T, membranes were incubated for 1 h with a 1:2000 dilution of peroxidase-conjugated anti-mouse IgG or anti-rabbit IgG (GE Healthcare) diluted in PBS-TM. After washing, the specific signal was detected using the Advanced ECL system (GE Healthcare) according to the manufacturer's instructions.
Analysis performed by Western blot yielded the results shown in
The emission of 40 ng of TSP was measured at 535 nm after being excited at 485 nm using a GENIOS fluorimeter. Each value was taken by measuring three times each extract. Results are shown in
Filing Document | Filing Date | Country | Kind | 371c Date |
---|---|---|---|---|
PCT/EP08/61580 | 9/2/2008 | WO | 00 | 5/6/2011 |